Figure 3From: Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control studyAt 24-month follow up, the overall survival rates for patients in adjuvant, palliative, and control group were 100% (5/5), 50% (3/6), and 16.7% (1/6), respectively. Patients in the adjuvant group had better overall survival than those in the palliative and control groups (p = 0.031).Back to article page